Advertisement

Übersicht therapierelevanter Antiepileptika zur Statusbehandlung

  • Hermann Stefan
  • Jürgen Bauer
Chapter
  • 12 Downloads
Part of the Kliniktaschenbücher book series (KTB)

Zusammenfassung

Die Behandlung der verschiedenen Formen von Status epileptici unterscheidet sich von derjenigen einer Dauertherapie. Dies liegt darin begründet, daß die Antiepileptika der ersten Wahl, nämlich Carbamazepin und Valproat, nicht zur parenteralen Applikation zur Verfügung stehen. Da beim Ausklingen des Status epilepticus die Fortsetzung einer oralen antiepileptischen Therapie notwendig ist zeigt Tabelle 4 die derzeitigen Antiepileptika der ersten Wahl.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

Allgemeiner Teil

  1. Fröscher W (1976) Therapie des Status epilepticus. Schattauer, StuttgartGoogle Scholar
  2. Herhahn J, Djonlagic H, Iven H ( 1989 ) Intensivmedizinische Arzneimitteltherapie. Marseille Verlag, MünchenGoogle Scholar
  3. Schmidt D (1981) Behandlung der Epilepsien. Thieme, StuttgartGoogle Scholar

zu Diazepam

  1. Bakker S (1983) Bioverfügbarkeit von rektalem Diazepam. In: Breimer DD (Hrsg) Rectal diazepam for acute therapy. Zuckschwerdt, München, S 7–12Google Scholar
  2. Bell DS (1969) Dangers of treatment of status epilepticus with diazepam. Br Med J 1: 714–715PubMedCrossRefGoogle Scholar
  3. Bittencourt PRM, Richens A (1981) Anticonvulsant-induced status epilepticus in Lennox-Gastaut syndrome. Epilepsia 22: 129–134PubMedCrossRefGoogle Scholar
  4. Booker HE, Celesia GG (1973) Serum concentrations of diazepam in subjects with epilepsy. Arch Neurol 29: 191–194PubMedCrossRefGoogle Scholar
  5. Browne TR (1976) Clonazepam: a review of a new anticonvulsant drug. Arch Neurol 33: 326–332PubMedCrossRefGoogle Scholar
  6. Browne TR (1983) Status epilepticus. In: Browne RT, Feldman RG (eds) Epilepsy: diagnosis and management. Little, Brown, Boston, pp 341–354Google Scholar
  7. Bülau P, Fröscher W, Schuchardt V, Kreiten K (1986) Prospektive randomisierte Untersuchung zur Wirksamkeit von Clonazepam and Diazepam beim Petit mal-Status. Nervenarzt 57: 667–671PubMedGoogle Scholar
  8. Cloyd JC, Gumnit RJ, McLain LW (1980) Status epilepticus. The role of intravenous phenytoin. JAMA 244: 1479–1481PubMedCrossRefGoogle Scholar
  9. Dam M, Christiansen J (1976) Diazepam: intravenous infusion in the treatment of status epilepticus. Acta Neurol Scand 54: 278–280PubMedCrossRefGoogle Scholar
  10. Delgado-Escueta AV, Wasterlain C, Treiman DM et al. (1982) Current concepts in neurology: Management of status epilepticus. N Engl J Med 306: 1337–1340PubMedCrossRefGoogle Scholar
  11. Ferngren HG (1974) Diazepam treatment for acute convulsions in children. Epilepsia 15: 27–37PubMedCrossRefGoogle Scholar
  12. Fröscher W (1987) Klinische Anwendung der Benzodiazepine in der Status-epilepticus-Behandlung. In: Kugler J, Leutner V (Hrsg) Benzodiazepine in der Neurologie. Editiones Roche, Basel, S 175–185Google Scholar
  13. Gastaut H, Naquet R, Poire R et al. (1965) Treatment of status epilepticus with diazepam ( Valium ). Epilepsia 6: 167–182PubMedCrossRefGoogle Scholar
  14. Gastaut H, Courjon J, Poire R, Weber M (1971) Treatment of status epilepticus with a new benzodiazepine more active than diazepam. Epilepsia 12: 197–214PubMedCrossRefGoogle Scholar
  15. Hall SC, Ovassapian A (1985) Apnea after intravenous diazepam therapy. JAMA 238: 1052CrossRefGoogle Scholar
  16. Mattson RH (1972) Benzodiazepines. In: Woodbury DM, Penry JK, Schmidt RD (eds) Antiepileptic drugs. Raven Press, New York, pp 497–518Google Scholar
  17. Nicol CF, Tutton JC, Smith BH (1969) Parenteral diazepam in status epilepticus. Neurology (Minneap) 19: 332–343Google Scholar
  18. Prensky AL, Raff MC, Moore NU et al. (1967) IV diazepam in the treatment of prolonged seizure activity. N Engl J Med 276: 779–784PubMedCrossRefGoogle Scholar
  19. Prior AF, MacLaine GN, Scott DF, Laurence BM (1972) Tonic status epilepticus precipitated by intravenous diazepam in a child with petit mal status. Epilepsia (Amst) 13: 467–472CrossRefGoogle Scholar
  20. Sawyer GT, Webster DD, Schut LJ (1968) Treatment of uncontrolled seizure activity with diazepam. JAMA 203: 913–918PubMedCrossRefGoogle Scholar
  21. Tassinari CD, Daniele O, Michelucci R et al. (1983) Benzodiazepines: efficacy in status epilepticus. In: Delgado-Escueta AV, Wasterlain CG, Treiman DM, Porter RJ (eds) Advances in neurology, Vol 34: Status epilepticus. Raven Press, New York, pp 465–476Google Scholar
  22. Treiman DM (1989) Pharmacokinetics and clinical use of benzodiazepines in the management of status epilepticus. Epilepsia 30: S4–S10PubMedCrossRefGoogle Scholar
  23. Wilder BJ, Ramsay RE, Willmore LJ, Feussner GF, Perchalski RJ, Shumate JB (1977) Efficacy of intravenous phenytoin in the treatment of status epilepticus: Kinetics of central nervous system penetration. Ann Neurol 1: 511–518PubMedCrossRefGoogle Scholar

zu Clonazepam

  1. Alvarez N, Hartford E, Doubt C (1981) Epileptic seizures induced by clonazepam. Clin Electroencephalogr 12: 57–63PubMedGoogle Scholar
  2. Bittencourt PRM, Richens A (1981) Anticonvulsant-induced status epilepticus in Lennox-Gastaut syndrome. Epilepsia 22: 129–134PubMedCrossRefGoogle Scholar
  3. Browne TR (1976) Clonazepam. A review of a new anticonvulsant drug. Arch Neurol 33: 327–332Google Scholar
  4. Browne TR (1978) Clonazepam. Engl J Med 299: 812–816CrossRefGoogle Scholar
  5. Congdon PJ, Forsythe WI (1980) Intravenous clonazepam in the treatment of status epilepticus in children. Epilepsia 21: 97–102PubMedCrossRefGoogle Scholar
  6. Gastaut H, Coupon J, Poire R, Weber M (1971) Treatment of status epilepticus with a new benzodiazepine more active than diazepam. Epilepsia 12: 197–214PubMedCrossRefGoogle Scholar
  7. Giunta F, Ottino CA, Rossi CF, Tercero E (1970) Studio esperimentale dell’azione antiepilettica di un nuovo derivato benzodiazepinico (Ro 5–4023). Riv Neurol 11: 213–223Google Scholar
  8. Gogolak G, Kolb R, Stumpf C (1970) Experimentelle Untersuchung über die konvulsive Wirkung von Benzylpenicillin, Ampicillin und Oxacillin. Wien Klin Wochenschr 82: 457–462PubMedGoogle Scholar
  9. Griffith PA, Karp HR (1979) Lorazepam in therapy for status epilepticus. Ann Neurol 7: 493CrossRefGoogle Scholar
  10. Ketz E, Bernoulli C, Siegfried J (1973) Klinische und hirnelektrische Prüfung von Clonazepam (Ro 5–4023) unter besonderer Berücksichtigung des Status epilepticus. Acta Neurol Scand 49 (Suppl 53): 47–53CrossRefGoogle Scholar
  11. Singh AN, le Morvan P (1982) Treatment of status epilepticus with intravenous clonazepam. Prog Neuropsychopharmacol Biol Psychiatry 6: 539–542PubMedCrossRefGoogle Scholar
  12. Walker JE, Homan RW, Vasco MR, Crawford JL, Bell RD, Tasker WG (1979) Lorazepam in status epilepticus. Ann Neurol 6: 207–213PubMedCrossRefGoogle Scholar

zu Clobazam

  1. Divoll M, Greenblatt DJ, Ciraulo DA, Puri SK, Ho I, Shader RI (1982) Clobazam kinetics: Intrasubjects variability and effect of food on absorption J Clin Pharmacol 22: 69–73Google Scholar
  2. Greenblatt DJ, Divoll M, Abernethy DR, Ochs HR, Shader RI (1983) Clinical pharmacokinetics of the newer benzodiazepines. Clin Pharmacokinet 8: 233–252PubMedCrossRefGoogle Scholar
  3. Greenblatt DJ, Divoll M, Puri SK, Ho I, Zinny MA, Shader RI (1981) Clobazam kinetics in the elderly. Br J Clin Pharmacol 12: 631–636PubMedGoogle Scholar
  4. Rupp W, Badian M, Christ O et al. (1979) Pharmacokinetics of single and multiple doses of clobazam in humans. Br J Clin Pharmacol 7: 518–528Google Scholar
  5. Tedeschi G, Riva R, Baruzzi A (1981) Clobazam plasma concentrations: Pharmacokinetic study in healthy volunteers and data in epileptic patients. Br J Clin Pharmacol 11: 619–622Google Scholar
  6. Tinuper P, Aguglia U, Gastaut H (1986) Use of clobazepam in certain forms of status epilepticus and in startle-induced epileptic seizures. Epilepsia 27:S18–S26PubMedCrossRefGoogle Scholar
  7. Valler JJ, Kotzan JA, Stewart JT, Honigberg IL, Needham TE, Brown WJ (1980) Plasma levels of clobazam after 10-, 20-, and 40-mg tablet doses in healthy subjects. J Clin Pharmacol 20: 444–451Google Scholar
  8. Vallner JJ, Needham TE, Jun HW, Brown WJ, Stewart JT, Kotzan JA, Honigberg IL (1978) Plasma levels of clobazam after three dosage forms in healthy subjects. J Clin Pharmacol 18: 319–324PubMedGoogle Scholar

zu Lorazepam

  1. Bell DS (1969) Dangers of treatment of status epilepticus with diazepam. Br Med J 1: 159PubMedCrossRefGoogle Scholar
  2. Comer WH, Elliott HW, Nomof N et al. (1973) Pharmacology of parenterally administered lorazepam in man. J Int med Res 1: 216Google Scholar
  3. Crawford TO, Mitchell WG, Snodgrass SR (1987) Lorazepam in childhood status epilepticus and serial seizures. Neurology 37: 190–195PubMedGoogle Scholar
  4. Elliott HW, Nomof N, Navarro G et al. (1971) Central nervous system and cardiovascular effects of lorazepam in man. Clin Pharmacol 12: 468–481Google Scholar
  5. Greenblatt DJ, Koch-Weser J (1973) Adverse reactions to intravenous diazepam. Am J Med Sci 266: 261–266PubMedCrossRefGoogle Scholar
  6. Greenblatt DJ, Shader RI (1974) Benzodiazepines in clinical practice. Raven Press, New YorkGoogle Scholar
  7. Greenblatt DJ, Comer WH, Elliott HW et al. (1977) Clinical pharmacokinetics of lorazepam: III. Intravenous injection: preliminary results. J Clin Pharmacol 17: 490–494Google Scholar
  8. Greenblatt DJ, Shader RI, Franke K et al. (1979) Pharmacokinetics and bio-availability of intravenous, intramuscular, and oral lorazepam in humans. J Pharm Sci 68: 57–63PubMedCrossRefGoogle Scholar
  9. Griffith PA, Karp HR (1979) Lorazepam in therapy for status epilepticus. Ann Neurol 6: 493Google Scholar
  10. Leppik IE, Derivan AT, Homan RW, Walker J, Ramsay RE, Patrick B (1983) Double-blind study of lorazepam and diazepam in status epilepticus. JAMA 249: 1452–1454PubMedCrossRefGoogle Scholar
  11. Walker JE, Homan RW, Vasko MR, Crawford IL, Bell RD, Tasker WG (1979) Lorazepam in status epilepticus. Ann Neurol 6: 207–213PubMedCrossRefGoogle Scholar
  12. Waltregny A, Dargent J (1976a) Preliminary study of parenteral lorazepam in status epilepticus. Acta Neurol Belg 75: 219–229Google Scholar
  13. Waltregny A, Dargent J (1976b) Preliminary report: Parenteral lorazepam in induced epileptic states in man. Acta Neurol Belg 76: 173–179PubMedGoogle Scholar

Vergleichsstudien-Literatur

  1. Bülau P, Fröscher W, Schuchardt V, Kreiten K (1986) Prospektive randomisierte Untersuchung zur Wirksamkeit von Clonazepam und Diazepam beim Petit mal-Status. Nervenarzt 57: 667–671PubMedGoogle Scholar
  2. Leppik IE, Derivan AT, Homan RW, Walker J, Ramsay RE, Patrick B (1983) Double-blind study of lorazepam and diazepam in status epilepticus. JAMA 249: 1452–1454PubMedCrossRefGoogle Scholar
  3. Shaner DM, McCurdy SA, Herring MO, Gabor AJ (1988) Treatment of status epilepticus: A prospective comparison of diazepam and phenytoin versus phenobarbital and optional phentoin. Neurology 38: 202–207PubMedGoogle Scholar
  4. Treiman DM (1989) Pharmacokinetiks and clinical use of benzodiazepines in the management of status epilepticus. Epilepsia 30: S4–S10PubMedCrossRefGoogle Scholar

zu Midazolam

  1. Allonen H, Ziegler G, Klotz U (1981) Midazolam kinetics. Clin Pharmacol Ther 30: 653–661PubMedCrossRefGoogle Scholar
  2. Collier PS, Kawar P, Gamble JAS, Dundee JW (1982) Influence of age on pharmacokinetics of midazolam. Br J Clin Pharmacol 13: 602Google Scholar
  3. Crevoisier C, Ziegler G, Eckert WH, Heizmann P (1983) Relationship between plasma concentration and effect of midazolam after oral and intravenous administration. Br J Clin Pharmacol 16: 51–61Google Scholar

Literatur zu Phenytoin

  1. Albert HH von (1983a) Phenytoin Infusion in the treatment of epilepsy. In: Parsonage M et al. (eds) Advances in epilepstology: XIVth Epilepsy International Symposium. Raven Press, New York, pp 307–312Google Scholar
  2. Albert HH von ( 1983b) Die Phenhydan-Schnellinfusion als Therapie der Wahl beim Status epilepticus. In: Remschmidt H, Rentz R, Jungmann J (Hrsg) Epilepsie 1981. Thieme, Stuttgart, S 183–185Google Scholar
  3. Albert HH von (1987) Phenytoin parenteral zur Therapie und Prophylaxe zerebraler Anfälle in der neurologischen Intensivmedizin Aktuell Neurol XVIIIGoogle Scholar
  4. Arznei-Telegramm (1986) Medikamentöse Prophylaxe und Therapie der Epilepsien (II). Arznei-Telegramm 10: 99–101Google Scholar
  5. Baldwin J, Amerson AB (1973) Intramuscular use of diphenylhydantoin. Am J Hosp Pharm 30: 837PubMedGoogle Scholar
  6. Cantu RC, Schwab RS, Timberlake WH (1968) Comparison of blood levels with oral and intamuscular diphenyhydantoin. Neurology (Minneap) 18: 782Google Scholar
  7. Chauplannaz G, Mauguiere F, Courjon J, Ferry S (1981) Use of intravenous phenytoin in treatment of partial status epilepticus. Nouv Presse Med 10: 1043–1046PubMedGoogle Scholar
  8. Cloyd JC, Bosch DE, Sawchuk RJ (1978) Concentration-time profile of phenytoin after admixture with small volumes of intravenous fluids. Am J Hosp Pharm 35: 45–48PubMedGoogle Scholar
  9. Cloyd JC, Gumnit RJ, McLain LW (1980) Status epilepticus. The role of intravenous phenytoin JAMA 244: 1479–1481Google Scholar
  10. Cote JR (1973) Intramuscular diphenylhydantoin. Ann Intern Med 78: 980PubMedGoogle Scholar
  11. Cranford RE, Leppik IE, Patrick B et al. (1978) Intravenous phenytoin: Clinical and pharmacokinetic aspects. Neurology 28: 874–880PubMedGoogle Scholar
  12. Dam M, Olesen V (1966) Intramuscular administration of phenytoin. Neurology (Minneap) 16: 288Google Scholar
  13. Delgado-Escueta AV, Treiman DM (1985) The emergency treatment of status epilepticus. In: Johnson KT (ed) Current therapy in neurologic disease. Decker, Philadelphia, pp 51–60Google Scholar
  14. Delegado-Escueta AV, Wasterlain C, Treiman DM, Porter RJ (1982) Management of status epilepticus. N Engl J Med 306: 1337–1340CrossRefGoogle Scholar
  15. Hansen H-W, Marquot B, Pelz W (1974) Anwendungstechnik und Therapieergebnisse mit einem Phenytoin-Infusionskonzentrat. Dtsch Med Wochenschr 99: 1961PubMedCrossRefGoogle Scholar
  16. Karbowski K (1974) Epileptische Manifestationen zerebrovasculärer Genese im Erwachsenenalter. Schweiz Rundsch Med 73: 765–771Google Scholar
  17. Kutt HK, Louis S, McDowell (1968) Intravenous diphenylhydantoin in experimental seizures ( I). Arch Neurol 18: 465–471PubMedCrossRefGoogle Scholar
  18. Laubscher FA (1966) Fatal diphenylhydantoin poisoning: a case report. JAMA 198: 1120–1121PubMedCrossRefGoogle Scholar
  19. Leppik IE, Patrick BK, Cranford RE (1983) Treatment of acute seizures and status epilepticus with intravenous phenytoin. In: Delgado-Escueta AV, Wasterlain CG, Treiman DM, Porter RJ (eds) Advances in neurology, Vol 34: Status epilepticus: mechanisms of brain damage and treatment. Raven Press, New York, pp 447–452Google Scholar
  20. Louis S, Kutt H, McDowell F (1968) Intravenous diphenylhydantoin in experimental seizures ( II ). Arch Neurol 18: 473–477CrossRefGoogle Scholar
  21. Masur H, Eiger CE, Ludoph AC (1988) Reversible und irreversible Kleinhirnaffektion nach einer einmaligen Intoxikation mit einer hohen Dosis Phenytoin-ein Vergleich zweier Fälle. In: Speckmann E-J, Palm DG (Hrsg) Epilepsie 1987. Einhorn Presse, Reinbek, S 318–321Google Scholar
  22. McWilliam PICA, Leeds MB (1958) IV phenytoin sodium in continuous convulsions in children. Lancet 11: 1147–1149CrossRefGoogle Scholar
  23. Murphy JT, Schwab RS (1956) Diphenylhydantoin ( Dilantin) sodium used parenterally in control of convulsions. JAMA 160: 385CrossRefGoogle Scholar
  24. Oelkers W, Schäfer H, Reith H (1975) Zur Anwendung eines PhenytoinInfusionskonzentrates im Kindesalter. Dtsch Med Wochenschr 100: 1012–1014PubMedCrossRefGoogle Scholar
  25. Schwab RS, Murphy JT (1959/60) Recent experiences with parenteral dilantin. Epilepsia (Amst) 1: 227CrossRefGoogle Scholar
  26. Serrano EE, Roye DB, Hammer RH, Wilder BJ (1973) Plasmo diphenylhydantoin values after oral and intramuscular administration of diphenylhydantoin. Neurology (Minneap) 23: 311Google Scholar
  27. Sherwin AL, Eisen AA, Sokolowski CD (1973) Correlation of anticonvulsant levels in human plasma and epileptogenic brain. Trans Am Neurol Assoc 98: 199–203PubMedGoogle Scholar
  28. Tichner JB, Enselberg CD (1951) Suicidal dilantin (sodium diphenylhydantoin). N Engl J Med 245: 723–725PubMedCrossRefGoogle Scholar
  29. Wallis W, Kutt H, McDowell F (1968) IV DPH in treatment of acute repetitive seizures. Neurology (Minneap) 18: 513–525Google Scholar
  30. Wilder BJ, Ramsey E, Willmore LJ, Feussner GF, Perchalski RJ, Shumate JB (1977) Efficacy in intravenous phenytoin in the treatment of status epilepticus: Kinetics of central nervous system penetration. An Neurol 1: 511–518CrossRefGoogle Scholar
  31. Wilensky AI, Lowden JA (1973) Inadequate serum levels after intramuscular administration of diphenylhydantoin. Neurology (Minneap) 23: 318Google Scholar

zu Barbituraten

  1. Amit R, Goitein KJ, Mathot I, Yatziv S (1988) Prolonged electrocerebral silent barbiturate come in intractable seizure disorderes. Epilepsia 29: 63–66PubMedCrossRefGoogle Scholar
  2. Arznei-Telegramm (1986) Medikamentöse Prophylaxe und Therapie der Epilepsie. Arznei-Telegramm 10: 99–101Google Scholar
  3. Brachet-Liermain A, Goutieres F, Aicardie J (1975) Absorption of phenobarbital after the intramuscular administration of single doses in infants. J Pediatr 87: 624–626PubMedCrossRefGoogle Scholar
  4. Brown A, Horton J (1967) Status epilepticus treated by intravenous infusions of thiopentone sodium. Br Med J I: 27–28PubMedCrossRefGoogle Scholar
  5. Cloyd JC, Gumnit RJ, McLain W (1980) Status epilepticus. The role of intravenous phenytoin, JAMA 244: 1479–1481PubMedCrossRefGoogle Scholar
  6. Corkill G, Silvalingam S, Reitan JA, Gilory B, Helphrey M (1978) Dose dependency of the post-insult protective effect of pentobarbital in the canine experimantal stroke model. Stroke 9: 10PubMedCrossRefGoogle Scholar
  7. Crawford TO, Mitchell WG, Fishman LS, Snodgrass SR (1988) Very-highdose phenobarbital for refractory status epilepticus in children. Neurology 38: 1035–1040PubMedGoogle Scholar
  8. Domek N, Barlow C, Roth L (1960) An ontogenetic study of phenobarbital-C(14) in cat brain. J Pharmacol Exp Ther 130: 285–293PubMedGoogle Scholar
  9. Donn SM, Grasela TH, Goldstein GW (1985) Safety of a higher loading dose of phenobarbital in the term newborn. Pediatrics 75: 1061–1064PubMedGoogle Scholar
  10. Goldberg MA, McIntyre HB (1983) Barbiturates in the treatment of status epilepticus. In: Delgado-Escueta AV, Wasterlain CG, Treiman DM; Porter RJ (eds) Advances in neurology, Vol 34: Status epilepticus. Raven Press, New York, pp 499–503Google Scholar
  11. Goldberg MA, Barlow C, Roth L (1961) The effects of carbone dioxide on the entry and accumulation of drugs in the central nervous system. J Pharmacol Exp Ther 131: 308–318PubMedGoogle Scholar
  12. Hoff JT, Smith AL, Hanikson HL, Nielsen SL (1975) Barbiturate protection from cerebral infarction in primates. Stroke 6: 28PubMedCrossRefGoogle Scholar
  13. Jailing B (1975) Plasma concentration of phenobarbital in the treatment of seizures in newborns. Acta Paediatr Scand 64: 514–524CrossRefGoogle Scholar
  14. Lockman LA (1983) Phenobarbital dosage for neonatal seizures. In: Delgado-Escueta AV, Wasterlain CG, Treiman DM, Porter RJ (eds) Advances in neurology, Vol 34: Status epilepticus. Raven Press, New York, pp 505–508Google Scholar
  15. Painter MJ, Pippenger, MacDonald H, Pitlick W (1978) Phenobarbital and diphenylhydantoin levels in neonates with seizures. J Pediatr 92: 315–319PubMedCrossRefGoogle Scholar
  16. Partinen M, Kovanen J, Nilsson E (1981) Status epilepticus treated by barbiturate anaesthesia with continuous monitoring of cerebral function. Br Med J 282: 520–521CrossRefGoogle Scholar
  17. Pascual J, Sedano MJ, Polo JM, Berciano J (1988) Intravenous lidocaine for status epilepticus. Epilepsia 29: 584–589PubMedCrossRefGoogle Scholar
  18. Pippenger CE, Rosen TS (1975) Phenobarbital plasma levels in neonates. Clin Perinatol 2: 111–115PubMedGoogle Scholar
  19. Raines A, Blake GJ, Richardson B (1979) Differential selectivity of several barbiturates on experimental seizures and neurotoxicity in the mouse. Epilepsia 20: 105–113PubMedCrossRefGoogle Scholar
  20. Rashkin MC, Youngs C, Penovich P (1987) Pentobarbital treatment of refractory status epilepticus. Neurology 37: 500–503PubMedGoogle Scholar
  21. Smith AL (1975) Barbiturate protection in cerebral hypoxia. Anesthesiology 47: 285CrossRefGoogle Scholar
  22. Smith AL, HofJT, Nielson SL, Larson CP (1975) Barbiturate protection in acute focal cerebral ischemia. Stroke 5: 1CrossRefGoogle Scholar
  23. Snead OC (1978) Gamma hydroxybutyrate in the monkey. Neurology 28: 1173–1178PubMedGoogle Scholar
  24. Wilensky A, Levy R, Friel P, Comfort C (1979) Phenobarbital pharmacokinetics after single IV, IM, and oral doses. Proc Am Epilepsy Soc (Abstr) 23: 37Google Scholar

zu Thiopental

  1. Herhahn J, Djoulagic H, Iven H (1989) Intensivmedizinische Arzneimitteltherapie. Marseille Verlag, MünchenGoogle Scholar

zu Clomethiazol

  1. Bittencourt PRM, Richens A (1981) Anticonvulsant-induced status epilepticus in Lennox-Gastaut syndrome. Epilepsia 22: 129–134PubMedCrossRefGoogle Scholar
  2. Moore RG, Triggs EJ, Shanks CA, Thomas J (1975) Pharmacokinetics of chlomethiazole in humans. Eur J Clin Pharmacol 8: 353PubMedCrossRefGoogle Scholar
  3. Pentikainen PJH, Neuvonen PJ, Jostell KG (1980) Pharmakokinetics of chlomethiazole in healthy volunteers and patients with cirrhosis of the liver. Eur J Clin Pharmacol 17: 275PubMedCrossRefGoogle Scholar
  4. Robson DJ, Blow C, Gaines P, Flanagan RJ, Henry JA (1984) Accumulation of chlomethiazole during intravenous infusion. Intensive Care Med 10: 315–316PubMedCrossRefGoogle Scholar
  5. Scott DB, Beamish D, Hudson IN, Jostell KG (1980) Prolonged infusion of chlomethiazole in intensive care. Br J Anaesth 52: 541PubMedCrossRefGoogle Scholar

zu Lidocain

  1. Astrup J, Sorensen PM, Sorensen HR (1981) Inhibition of cerebral oxygen and glucose consumption in the dog by hypothermia, pentobarbital and lidocaine. Anesthesiology 55: 263–268PubMedCrossRefGoogle Scholar
  2. Bernhard CG, Bohm E (1965) Local anaesthetics as anticonvulsants. Almquist & Wiksell, UppsalaGoogle Scholar
  3. Bigger JT (1980) Management of arrythmias. In: Braunwald E (ed) Heart disease. Saunders, Philadelphia, pp 691–743Google Scholar
  4. Browne TR (1983a) Status epilepticus. In: Browne RT, Feldman RG (eds) Epilepsy: diagnosis and management. Little & Brown, Boston, pp 341–354Google Scholar
  5. Browne TR (1983b) Paraldehyde, chlomethiazole and lidocaine for treatment of status epilepticus. In: Delgado-Escueta AV, Wasterlain CG, Treiman DM, Porter RJ (eds) Avances in neurology, Vol 34: Status epilepticus: mechanisms of brain damage and treatment. Raven Press, New York, pp 509–517Google Scholar
  6. Evans DE, Kobrine AI, LeGrys DC, Bradley ME (1984) Protective effect of lidocaine in acute cerebral ischemia induced by air embolism. J Neurosurg 60: 257–163PubMedCrossRefGoogle Scholar
  7. Haschke R, Fink R (1975) Lidocaine effects of brain mitochondrial metabolism in vitro. Anesthesiology 42: 737–740PubMedCrossRefGoogle Scholar
  8. Lemmen LJ, Klassen M, Druiser B (1978) Intravenous lidocaine in the treatment of convulsions. JAMA 239: 2025PubMedCrossRefGoogle Scholar
  9. Morris HH (1979) Lidocaine: A neglected anticonvulsant? South Med J 72: 1564–1566PubMedCrossRefGoogle Scholar
  10. Pascual J, Sedano MJ, Polo JM, Berciano J (1988) Intravenous lidocaine for status epilepticus. Epilepsia 29: 584–589PubMedCrossRefGoogle Scholar
  11. Ritchie JM, Greene NM (1985) Local anesthetics. In: Goodman Gilman A, Goodman LS, Rall TW, Murald F (eds) The pharmacological basis of therapeutics. Macmillan, New York, pp 302–321Google Scholar
  12. Sakabe T, Maekana T, Ishikawa T, Takeshita H (1974) The effect of lidocaine on canine cerebral metabolism and circulation related to the electroencephalogram. Anesthesiology 40: 433–441PubMedCrossRefGoogle Scholar
  13. Taverner D, Bain WA (1958) Intravenous lidocaine as an anticonvulsant in status epilepticus and serial epilepsy. Lancet 11: 1145–1147CrossRefGoogle Scholar
  14. Tsukamoto S, Horiike N, Hisinaga M, Utsumi S (1980) The efficiacy of lidocaine in status epilepticus. Brain Nerve 32: 363–368PubMedGoogle Scholar
  15. Wagman IH, Calif D, de Jong RH, prince DA (1968) Effects of lidocaine on spontaneous cortical and subcortical electrical activity. Arch Neurol 18: 277–290PubMedCrossRefGoogle Scholar
  16. Westreich DM (1972) Intravenous lidocaine for status epilepticus. Minn Med 55: 807–809PubMedGoogle Scholar
  17. Ying-K’un F, Shu-Lein Y, Ya-hsin F (1963) The effect of intravenous xylocaine on status epilepticus. Chin Med J 2: 668–673Google Scholar

zu Paraldehyd

  1. Anthony R, Andorn A, Sunshine I et al. (1977) Paraldehyde pharmacokinetics in ethanol abusers. Fed Proc 36: 285Google Scholar
  2. Beauchemin J, Springer R, Elliot G (1935) Intravenous anesthesia with paraldehyde. Med Times 63: 177–184Google Scholar
  3. Beier L, Pitts W, Gonick H (1963) Metabolic acidosis during paraldehyde intoxication. Ann Intern Med 58: 155–158PubMedGoogle Scholar
  4. Bodansky M, Jinkins J, Levine H et al. (1941) Clinical and experimental studies on paraldehyde. Anesthesiology 2: 20–27CrossRefGoogle Scholar
  5. Bostrom B (1982) Paraldehyde toxicity during treatment of status epilepticus. Am J Dis Child 136: 414–415PubMedGoogle Scholar
  6. Burstein C (1943) The hazard of paraldehyde administraion. JAMA 121: 187–190CrossRefGoogle Scholar
  7. De Elio F, De Jalon P, Obrador S (1949) Some experimental and clinical observations on the anticonvulsant action of paraldehyde. J Neurol Neurosurg Psychiatry 12: 19–24CrossRefGoogle Scholar
  8. Figot P, Hine C, Way E (1952) The estimation and significance of paraldehyde levels in blood and brain. Acta Pharmacol Toxicol 8: 290–304CrossRefGoogle Scholar
  9. Gardner H, Sage E (1941) The intravenous administration of paraldehyde during labor. Am J Obstet Gynecol 42: 467–472Google Scholar
  10. Gooch W, Kennedy B, Banner W et al. (1979) Generalized arterial and venous thrombosis following intraarterial paraldehyde. Clin Toxicol 15: 39–44PubMedCrossRefGoogle Scholar
  11. Kittel J (1973) Paraldehyde toxicity. Hosp Pharmacy 8: 263–265Google Scholar
  12. Kotz J, Roth G, Ryon W (1938) Indiosyncrasy to paraldehyde. JAMA 110: 2145–2148CrossRefGoogle Scholar
  13. Levine H, Gilbert A, Bodansky M (1939) The effect of liver damage on the blood level and action of paraldehyde. J Pharmacol Exp Ther 67: 299–305Google Scholar
  14. Sinal S, Crowe J (1976) Cyanosis, cough, and hypotension following intravenous administration of paraldehyde. Pediatrics 57: 158–159Google Scholar
  15. Thurstone J, Liang H, Smith J et al. (1968) New enzymatic method for measurement of paraldehyde: Correlation of effects with serum and CSF levels. J Lab Clin Med 72: 699–704Google Scholar
  16. Whitty C, Taylor M (1949) Treatment of status epilepticus. Lancet 11: 591–594CrossRefGoogle Scholar
  17. Woodbury D, Fingl E (1975) Drugs effective in the therapy of the epilepsies. In: Goodman LS, Gilman A (eds) The pharmacological basis of therapeutics, 5th edn. Macmillan, New York, pp 201–226Google Scholar

zu Althesiu

  1. Bimar J, Lepouleuf (1973) Les effets sur le systeme nerveux central du CT 1341. Ann Anesth Franc 14: 491–514Google Scholar
  2. Chacornac R, Convert J, DeLeuze R (1973) Emploi du 1341 en neurochirurgie. Ann Anesth Franc 14: 565–571Google Scholar
  3. Emperaire N, Bimar J (1970) Etude neurophysiologique du CT 1431. Mediterr Med 1: 237–262Google Scholar
  4. Munari C, Casaroli D, Matteuzzi G, Pacifico L (1979) The use of althesin in drug-resistant status epilepticus. Epilepsia 20: 475–484PubMedCrossRefGoogle Scholar
  5. Pickerodt V, McDowal DG, Coroeos NJ, Keaney NP (1972a) Effect of althesin on carotid blood flow and intracranial pressure in the anaesthetized baboon: preliminary communication. Postgrad Med J 48 (Suppl 2): 58–61PubMedGoogle Scholar
  6. Pickerordt V, McDowal DG, Coroneos NJ, Keaney NP (1972b) Effect of althesin on cerebral perfusion, cerebral metabolism and intracranial pressure in the anaesthezised baboon. Br J Anaesth 44: 751–757CrossRefGoogle Scholar
  7. Strunin L, Strunin JM, Knights KM, Ward ME (1977) Metabolism of 14C-labeled alfacalone in man. Br J Anaesth 49: 605–614CrossRefGoogle Scholar
  8. Takahashi T, Takahashi M, Namiki A, Dohi S (1973) Effects of althesin on cerebrospinal fluid pressure. Br J Anaesth 45: 179–184PubMedCrossRefGoogle Scholar
  9. Turner JM, Coroneos NY, Gibson RM, Powell D, Ness MA, McDowall DG (1973) The effect of althesin on intracranial pressure in man. Br J Anaesth 45: 168–172PubMedCrossRefGoogle Scholar
  10. Uppington Y (1973) Epileptiform convulsion with althesin. Anaesthesia 28: 546–550PubMedCrossRefGoogle Scholar

zu Isoflurane und Enflurane

  1. Blich HP, Bich U (1977) Narkotika. In: Forth W, Henschler D, Rummel W (Hrsg) Pharmakologie und Toxikologie. Bibliographisches Institut, Mannheim, S 388–394Google Scholar
  2. Burchiel KJ, Stockard JJ, Myers RR, Bickford RG (1975) Epileptogenicity of enflurane and isoflurane. Texas Rep Biol med 33: 562Google Scholar
  3. Dworacek B, de Vliegere M (1984) Absence of electroencephalographic excitation pattern under isoflurane anesthesia. Acta Anaesth Belg 35: 211–217PubMedGoogle Scholar
  4. Fariello RG (1980) Epileptogenic properties of enflurane and their clinical interpretation. Electroencephalogr clin Neurophysiol 48: 595–598PubMedCrossRefGoogle Scholar
  5. Ito BM, Sato S, Kufta CV, Tran D (1988) Effect of isoflurane and enflurane on the electrocorticogram of epileptic patients. Neurology 38: 924–928PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1990

Authors and Affiliations

  • Hermann Stefan
    • 1
  • Jürgen Bauer
  1. 1.Neurologische UniversitätsklinikErlangenDeutschland

Personalised recommendations